In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
Attached is KEI’s February 8, 2018 submission to USTR, regarding the 2018 Special 301 list. Special301-KEI-Submission-8Feb2018 We also have all 29 years of Special 301 Reports, from 1989 to 2017, available here: https://keionline.org/ustr/special301
Knowledge Ecology International and 43 other health-care interested groups are calling on Congress to pass the CREATES Act. The CREATES Act, or the “Creating and Restoring Equal Access To Equivalent Samples Act of 2017”, is a bipartisan proposal to speed… Continue Reading
After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.8 on Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018 the either… Continue Reading
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.7 on the Global strategy and plan of action on public health, innovation and intellectual property either on Wednesday, 24 January 2018 or Thursday, 25 January 2018.… Continue Reading
On Wednesday, 24 January 2018, the World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.6 on Addressing the global shortage of, and access to, medicines and vaccines. Non-state actors in official relations with the WHO are… Continue Reading
On January 15, 2018, PhRMA provided comments on the Colombian Resolution 5246, a public interest declaration for several drugs for the hepatitis c virus (HCV). A copy of the PhRMA letter is attached below. It is a combination of complaints… Continue Reading
In November 2017, the World Health Organization (WHO) published a report charting a path forward for the expansion of WHO’s work on the transparency of R&D costs and medicines prices while rekindling the prospects for WHO to assume the mantle of… Continue Reading